Critical Overview of HER2 Assessement in Bladder Cancer: What Is Missing for a Better Therapeutic Approach?
- PMID: 28870915
- DOI: 10.21873/anticanres.11903
Critical Overview of HER2 Assessement in Bladder Cancer: What Is Missing for a Better Therapeutic Approach?
Abstract
Background/aim: To assess the concordance between IHC and FISH and its influence on tumor type, grade and lympho-vascular invasion (LVI).
Materials and methods: HER2 immunohistochemistry (IHC) to 45 cases of bladder carcinoma, followed by fluorescent in situ hybridization (FISH) were applied.
Results: 31.12% cases were IHC positive. Less than 35% of HER2-negative cases presented LVI and this percent increased to 54.54% for +1 HER2 cases. LVI increases up to 57.14% for +2 HER2 cases and slightly decreased for +3 HER2 cases to 42.85%. IHC/FISH concordance was found for 73.34% cases but 31.57% were previously negative and 36.36% scored as +1 by IHC had gene amplification as shown by FISH analysis. T3 was correlated with HER2-IHC (p=0.05) and HER2-FISH (p=0.01).
Conclusion: Improved HER2 assessement is needed for urothelial carcinomas. HER2-IHC scored as 0-2 should be validated by and reclassified according to FISH analysis.
Keywords: HER2; bladder cancer; fluorescent in situ hybridization; immunohistochemistry.
Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Similar articles
-
HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role.Int J Mol Sci. 2023 Feb 13;24(4):3720. doi: 10.3390/ijms24043720. Int J Mol Sci. 2023. PMID: 36835131 Free PMC article. Review.
-
Primary squamous cell carcinoma of the breast: report of two cases with HER2 overexpression.Cancer Biol Ther. 2020 Dec 1;21(12):1081-1086. doi: 10.1080/15384047.2020.1838033. Epub 2020 Nov 12. Cancer Biol Ther. 2020. PMID: 33180662 Free PMC article. Review.
-
HER2 Status in Gastroesophageal Adenocarcinomas: Correlation Between Immunohistochemistry and Fluorescence In Situ Hybridization Methodologies.Appl Immunohistochem Mol Morphol. 2018 Jan;26(1):35-39. doi: 10.1097/PAI.0000000000000382. Appl Immunohistochem Mol Morphol. 2018. PMID: 27153447
-
HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder.Dis Markers. 2016;2016:8463731. doi: 10.1155/2016/8463731. Epub 2016 Mar 10. Dis Markers. 2016. PMID: 27034533 Free PMC article.
-
HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.Lung Cancer. 2014 Sep;85(3):373-8. doi: 10.1016/j.lungcan.2014.06.007. Epub 2014 Jul 7. Lung Cancer. 2014. PMID: 25047676
Cited by
-
The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2 Expression.Cancers (Basel). 2023 Dec 6;15(24):5721. doi: 10.3390/cancers15245721. Cancers (Basel). 2023. PMID: 38136267 Free PMC article.
-
HER2 expression in urothelial carcinoma, a systematic literature review.Front Oncol. 2022 Oct 21;12:1011885. doi: 10.3389/fonc.2022.1011885. eCollection 2022. Front Oncol. 2022. PMID: 36338710 Free PMC article.
-
The Clinical Significance and Prognostic Value of HER2 Expression in Bladder Cancer: A Meta-Analysis and a Bioinformatic Analysis.Front Oncol. 2021 Sep 1;11:653491. doi: 10.3389/fonc.2021.653491. eCollection 2021. Front Oncol. 2021. PMID: 34540657 Free PMC article.
-
Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans.Front Oncol. 2020 Jan 21;9:1493. doi: 10.3389/fonc.2019.01493. eCollection 2019. Front Oncol. 2020. PMID: 32039002 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
